Bradley Merrill Thompson and Chris Bergstrom

Bradley Merrill Thompson is a member of the firm at Epstein Becker & Green, P.C. There, he counsels medical device, drug, and combination product companies on a wide range of FDA regulatory issues.

Chris Bergstrom is a digital health leader, for The Boston Consulting Group (BCG). At BCG, he directs digital health initiatives across large payer, provider, med tech, and bio/pharma companies. In doing so, he leverages the best of BCG Consulting, BCG Digital Ventures, BCG Gamma Data-Science, and B.Capital to help clients formulate a strategy, build a solution, and jointly invest in greenfield ventures or new business units.

Five regulatory myths keeping bio/pharma out of digital health

By Bradley Merrill Thompson and Chris Bergstrom 09:22 am October 27, 2017

About the Authors: Bradley Merrill Thompson is a member of the firm at Epstein Becker & Green, P.C. There, he counsels medical device, drug, and combination product companies on a wide range of FDA regulatory issues. Chris Bergstrom is a digital health leader, for The Boston Consulting Group (BCG). At BCG, he directs digital health initiatives across large payer, provider, med tech, and bio/...